- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01130376
Novel Interventions in HIV-1 Infection (IMIRC1003)
A Randomised, Open Labelled, Phase I, Safety, Toxicity, and Exploratory Immunogenicity Evaluation of Therapeutic Immunisation +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy
For several years there has been interest in why some people with HIV-1 progress more slowly to disease and have longer survival without Highly Active Antiretroviral Therapy (HAART) than others. The investigators and others have identified a few HIV positive individuals who can control their viral load for many years without HAART, these rare individuals do not lose their HIV-1-specific cellular immune responses, which are very important for controlling viral load. This group is referred to as long-term non-progressors (LTNP). Unlike LTNP the majority of HIV-1 infected individuals are chronic progressors (CP) who do not make effective HIV-1-specific cellular immune responses, even when on HAART. We propose to use a novel DNA vaccine boosted with immune based therapy (cytokines and hormones) to try to regenerate the missing HIV-1-specific cellular immune responses to make chronically infected HIV-1+ persons more like LTNP.
By injecting this novel DNA vaccine and immune based therapy into the people who are already infected with HIV-1, the immune system may be stimulated to mount a greater immune response not only to the vaccines but also to real HIV-1 particles and HIV-1-infected cells.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This will be a randomised, Phase I, open label comparative study running for 52 weeks (2 screen visits 2 weeks apart followed by 48 weeks of study). 50 patients will be screened in the initial phase of which 30 clade B infected individuals will be randomised into the study, which will consist of 3 arms:
Arm 1 will ascertain vaccine safety and toxicity in the presence of cytokine/hormone therapy.
Arm 2 will identify vaccine safety and toxicity.
Arm 3 will indicate safety and toxicity of cytokine/hormone therapy.
The target patients are chronically HIV-1 clade B infected persons who will have had a nadir CD4 T-cell count of >200 cells/ul blood before they started ART. The current CD4 T-cell count should be >400 cells/ul blood. Patients may have received ART for any length of time, but currently should be receiving NNRTI or boosted-PI based HAART, and have a viral load below the level of detection (50 copies/ml plasma). Patients will be bled on two occasions before commencing IBT regimens, in order to establish baselines, and then at regular intervals thereafter (weeks 0,1,2,4,6,8,12,16,24 and 48).
The treatment regimens are consistent with previous findings in animal models which suggest that administration of IL-2 during the antigen-specific T-cell contraction phase of an immune response (between 8 and 15 days post-vaccination) may preserve and lengthen clinically relevant responses. Furthermore studies in man have demonstrated that IL-2 administered before immunisation in ART-treated HIV-1-infected patients does not increase specific lymphoproliferation of T cells.
Recent preliminary studies in HIV-1-infected individuals using tetanus vaccines the investigators have shown that IL-2 administered after immunisation may be more effective at inducing sustained tetanus-specific responses than IL-2 administered before immunisation or together with immunisation. The dosages used in this study are based on those used in previous pilot studies of the administration of IL-2 + GM-CSF and rhGH and at these levels the drugs have been shown to have both positive effect on the immune response and demonstrated clinical benefit whilst being at a level which is safe and well tolerated in HIV-1 positive individuals. The dosage of the vaccine was based on a previous study where a dosage of this level has been shown to induce an immune response although this response was transient. In summary the investigators aim to increase the survival of vaccine responses through the administration of cytokines/hormones and boost memory responses with further rounds of immunisation.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
London, Regno Unito, SW10 9NH
- St. Stephen's AIDS Trust
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Documented HIV-1 positive result.
- Stable on HAART.
- Two screening viral loads of <50 cps/ml on 2 consecutive occasions at least one month apart.
- CD4 T cell count of >400 cells/ul.
- Nadir CD4 T cell count of >200 cells/ul.
- Over 18 years of age.
- Willing and able to provide informed consent.
- Female subjects must not be pregnant or lactating.
- Subjects must be using adequate double barrier method of contraception as appropriate.
Exclusion Criteria:
- Prior therapeutic vaccination.
- Acute illness within 2 weeks of the start of the study.
- Prior immunomodulatory therapy (e.g. IL-2, rhGH, GCSF, GM-CSF, HU)
- Receiving immunosuppressive medication (e.g. Steroids)
- Participation in other vaccine trials currently
- Patients with diabetes mellitus type 2
- Patients with cardiac abnormalities
- Patients with pre-existing autoimmune disease
- Patients with active neoplasia
- Patients with evidence of any progression or recurrence of an underlying intra-cranial lesion
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Vaccine and cytokines
Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection. Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections. Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC. Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection. |
Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
Altri nomi:
150 ug administered subcutaneously once daily 4 hours from IL-2 injections
Altri nomi:
4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
Altri nomi:
|
Comparatore attivo: Vaccine alone
Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections. Day 42: GTU-MultiHIV B clade vaccine as day 0. Day 84: GTU-MultiHIV B clade vaccine as day 0. |
Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
|
Comparatore attivo: Cytokines alone
Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections. Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC. |
5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
Altri nomi:
150 ug administered subcutaneously once daily 4 hours from IL-2 injections
Altri nomi:
4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
The primary outcome will be analysis of safety and toxicity data in relation to grade 3 or above laboratory or clinical serious adverse event (SAE) which can be attributed to the treatments given
Lasso di tempo: Weekly
|
Weekly
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
The secondary immunological outcomes will be percentage change from baseline to study time point in defined cellular immune responses.
Lasso di tempo: weekly
|
weekly
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Nesrina Imami, MD/PhD, Imperial College London
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni
- Effetti fisiologici delle droghe
- Agenti antinfettivi
- Agenti del sistema nervoso periferico
- Agenti antivirali
- Agenti anti-HIV
- Agenti antiretrovirali
- Analgesici
- Agenti del sistema sensoriale
- Analgesici, non narcotici
- Agenti antineoplastici
- Fattori immunologici
- Ormoni, sostituti ormonali e antagonisti ormonali
- Aldesleukin
- Ormoni
- Sargramostim
- Interleuchina-2
Altri numeri di identificazione dello studio
- CRO930
- G0501957 (Altro numero di sovvenzione/finanziamento: Medical Research Council UK)
- 2008-000575024 (Identificatore di registro: EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezione da HIV-1
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... e altri collaboratoriCompletatoHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesCompletato
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaCompletato
-
Gilead SciencesCompletato
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...Completato
-
Tibotec Pharmaceuticals, IrelandCompletatoHIV-1Stati Uniti, Francia, Spagna, Portogallo, Canada, Regno Unito, Sud Africa, Argentina, Brasile, Porto Rico, Tailandia, Olanda, Romania
-
Tibotec Pharmaceuticals, IrelandCompletatoHIV-1Stati Uniti, Canada, Francia, Belgio, Germania, Spagna, Argentina, Chile, Panama, Brasile, Porto Rico, Tailandia, Messico, Australia
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; CEVAC e altri collaboratoriCompletato
-
Janssen Pharmaceutica N.V., BelgiumCompletato
Prove cliniche su GTU-MultiHIV B clade vaccine1mg
-
Imperial College LondonCUT'HIVAC Cutaneous HIV VaccinationSconosciuto
-
ANRS, Emerging Infectious DiseasesImperial College London; University College, London; Fred Hutchinson Cancer Center e altri collaboratoriTerminatoInfezione da HIV-1Svizzera, Regno Unito
-
ANRS, Emerging Infectious DiseasesCompletato
-
ANRS, Emerging Infectious DiseasesCompletato
-
National Institute of Allergy and Infectious Diseases...CompletatoInfezioni da HIVStati Uniti